Moscow, Russia, July 25, 2017 – InSysBio LLC (www.insysbio.ru), one of the pioneers in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a renewal of multi-year Master Service Agreement with ASTEX Pharmaceuticals, Inc.
Within the framework of this cooperation, InSysBio provides priority support for ASTEX research. This gives an opportunity to access the best practices of InSysBio in the field of QSP modeling, as well as significantly reduce the time of initiation and execution of projects.
The renewal of the ASTEX agreement once again shows that QSP is a necessary technology to support discovery and development of new drugs in oncology and immuno-oncology therapeutic areas. Such an approach improves all stages of the development: it helps to make strategic GO/ NO GO decisions for research, prioritize targets and compounds, interpret results from animal studies and select optimal design(s) for clinical trials.
"We are very pleased ASTEX has chosen to renew our multi-year Master Service Agreement. It underscores that our partners are satisfied with our services and would like to extend this fruitful and reliable collaboration," said Founder and CEO Oleg Demin, PhD.
| ← | October 2021 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
| ||||
|
4
|
5
|
6
1.
06 Oct 2021 14:56
InSysBio to start the lectures at Lomonosov Moscow State University
InSysBio expert modeler Tatiana Karelina will give the lectures on QSP modeling for the Master's degree students at the Faculty of Physics, Lomonosov Moscow State University.
|
7
|
8
|
9
|
10
|
|
11
|
12
1.
12 Oct 2021 10:58
InSysBio to start its annual course at Lomonosov Moscow State University
This year InSysBio CEO Oleg Demin and Head of IRT team Veronika Musatova are giving the course "Mathematical modeling in systems biology and biomedicine" at the Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University.
|
13
|
14
|
15
|
16
|
17
|
|
18
|
19
|
20
|
21
|
22
|
23
|
24
|
|
25
|
26
|
27
|
28
|
29
|
30
|
31
|
Thank you for your message! We will get back to you shortly.
